Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

708 - Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF 06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC)

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy

Presenters

Siwen Hu-Lieskovan

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

M. Johnson1, S. Hu-Lieskovan2, F.S. Braiteh3, J. Grilley-Olson4, J. Chou5, J. Davda6, B. Jin7, A. Forgie5, D. Rassam6, S. Youssef5

Author affiliations

  • 1 Oncology, Sarah Cannon Research Institute, 37203 - Nashville/US
  • 2 School Of Medicine, UCLA, 90095 - Los Angeles/US
  • 3 Medical Oncology, Comprehensive Cancer Centers of Nevada, 89169 - Las Vegas/US
  • 4 Hematology/oncology, University of North Carolina, 27514 - Chapel Hill/US
  • 5 Research And Development, Pfizer, 94080 - South San Francisco/US
  • 6 Research And Development, Pfizer, 92121 - La Jolla/US
  • 7 Biostatistics, Pfizer, Cambridge/US
More

Resources

Abstract 708

Background

PF-06801591, a humanized IgG4 monoclonal antibody, blocks the Programmed Cell Death (PD-1) pathway by binding with high affinity to PD-1 and preventing its interaction with its ligands. A phase 1 study to assess the safety and tolerability of PF-06801591 after IV or SC administration is ongoing in patients (pts) with locally advanced or metastatic solid tumors.

Methods

PF-06801591 was administered at 0.5, 1, 3, or 10 mg/kg IV once every 3 weeks (q3w), or 300 mg SC once every 4 weeks (q4w). Dose escalation occurred after the first 2-4 pts at each dose cohort, with additional pts then enrolled to each cohort for further PD assessment. Safety, tolerability, PK, and PD were assessed for all pts.

Results

As of January 31, 2017, 26 pts (ovarian cancer, n = 12; sarcoma, n = 6; head and neck cancer [SCCHN]; n = 5; melanoma, n = 1; small cell lung cancer, n = 1; and malignant peritoneal neoplasm, n = 1) were treated in the dose-escalation phase: 0.5 (n = 2), 1 (n = 8), 3 (n = 7), 10 (n = 5) mg/kg IV, and 300 mg (n = 4) SC. Maximum tolerated dose was not reached. No drug-related SAEs or dose-limiting toxicities were observed. All drug-related AEs were Grade 1 or 2, and the most frequently reported in > 15% of pts include nausea (15.4%) and fatigue (15.4%). No dose-dependency of AEs was observed during IV dose escalation nor serious skin toxicity with SC administration. Four pts had partial response at 0.5, 1, and 10 mg/kg IV (ovarian pts) and 300 mg SC (SCCHN pt) and 3 pts had stable disease lasting >24 wks. There was a dose-dependent increase in the maximum concentration (Cmax) and area under the concentration-time curve (AUC) after IV administration. Following SC administration, PF-06801591 was slowly absorbed, with a median time to Cmax of 182 hours. The mean average concentration (Cav) after the first SC dose at 300 mg q4w was approximately 50% of the mean Cav following IV administration at 3 mg/kg q3w. Full receptor occupancy of PD-1 was seen in all dose cohorts.

Conclusions

Preliminary results demonstrate that PF-06801591 is well-tolerated with objective responses observed across the dose levels tested in both IV and SC forms. PK data confirmed the appropriateness of the dosing frequency.

Clinical trial identification

NCT02573259

Legal entity responsible for the study

Pfizer Inc.

Funding

Pfizer Inc.

Disclosure

S. Hu-Lieskovan: Consulting: Amgen, Merck, Novartis, Vaccinex, Emergent BioSolutions Contracted Research: Pfizer, Plexxikon, Genentech, Neon Therapeutics Research Support: Bristol-Myers Squibb, Merck Travel Support: Amgen, Merck, Novartis, Vaccinex, Emergent BioSolutions, Neon Thera. M. Johnson: Research funding (institution): OncoMed, BerGenBio, Lilly, EMD Serono, Kadmon, Janssen, Mirati, Genmab, Pfizer, AstraZeneca, Genentech/Roche Stemcentrix, Novartis, and others; compensation (institution) from Genentech/Roche, Celgene and Boehringer Ingelheim. F.S. Braiteh: Speaker and advisor/consultant for Pfizer. J. Grilley-Olson: Only disclosures are for Institutional research funding from: Pfizer, Genentech, Novartis, Seattle Genetics, Medimmune, Nanocarrier. J. Chou J. Davda, B. Jin, A. Forgie: Employed by Pfizer and own Pfizer stock. D. Rassam, S. Youssef: Pfizer consultant but privately own Pfizer stock.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.